Clinical Trials · NCT03436654
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 102
- Start date
- Jun 2018
- Locations
- 11 sites, United States
- Primary endpoint
- Pathologic Response (pCR + MRD) in the RP specimen